Providing open-label placebos remotely-A randomized controlled trial in allergic rhinitis

Area of Science:

• Psychosomatic Medicine
• Clinical Psychology
• Integrative Medicine

Background:

• Open-label placebos (OLPs) demonstrate symptom reduction potential, yet mechanisms and remote efficacy remain debated.
• The COVID-19 pandemic highlighted the need for remote healthcare delivery, including placebo interventions.
• Understanding the impact of the clinical encounter on OLP effectiveness is crucial.

Purpose of the Study:

• To evaluate the efficacy of remotely administered OLPs for allergic rhinitis symptom reduction.
• To investigate the influence of virtual clinical encounter quality (augmented vs. limited) on OLP effectiveness.
• To compare OLP plus treatment as usual (TAU) against TAU alone.

Main Methods:

• A randomized-controlled trial with 54 participants with allergic rhinitis.
• Remote OLP administration via postal service due to the COVID-19 pandemic.
• Manipulation of virtual clinical encounter perception (verbal and nonverbal factors).

Main Results:

• All participants showed symptom reduction; OLPs did not provide incremental benefit over TAU.
• OLP effectiveness was greater in participants not using other allergy medications.
• A significant interaction indicated greater symptom improvement in the OLP group with augmented encounters.

Conclusions:

• Remote OLP administration and virtual encounter enhancement are feasible but may be less effective than in-person interactions.
• Further research is needed on the potential and challenges of remote placebo interventions and virtual clinical encounters.
• The study registered at ISRCTN (record number: 39018) provides insights into remote psychosomatic interventions.